A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to <12 years of age.

开始日期2025-06-05

申办/合作机构

Bavarian Nordic A/S

NCT06007183

/ Active, not recruiting临床3期

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial CHIKV VLP vaccination.

开始日期2023-08-30

申办/合作机构

Bavarian Nordic A/S

NCT05349617

/ Completed临床3期

A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age

The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.

开始日期2022-05-12

申办/合作机构

Bavarian Nordic A/S

[+1]

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的临床结果

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的转化医学

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的专利（医药）

登录后查看更多信息

113

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的文献（医药）

2026-02-01·Current Opinion in Virology

A storm is born: immune activation and pathogenesis in arthritogenic alphavirus infections

Review

作者: Koo, Yong Qian ; Freppel, Wesley ; Herrero, Lara J

Arthritogenic alphaviruses, including chikungunya (CHIKV), Ross River, and Mayaro viruses, are emerging global viruses responsible for causing arthralgia and chronic arthritis. Following mosquito-borne transmission, they quickly initiate infection in the skin, including in resident immune cells, and disseminate systemically into musculoskeletal tissues. The innate immune system responds rapidly through the activation of interferons, the production of inflammatory cytokines, and the recruitment of monocytes, macrophages, neutrophils, and dendritic cells, while the adaptive immune response, particularly virus-specific T and B cells, is critical for viral clearance. However, excessive immune activation can lead to both acute and chronic musculoskeletal pain through cytokine storm, tissue damage, and supporting immunopathology. Additionally, viral persistence and immune evasion may contribute to the development of chronic synovitis and cartilage degradation, leading to persistent joint pain. Despite recent advances, antiviral treatments remain unavailable, and to date, there is only one vaccine licensed (VIMKUNYA™ in 2025, against CHIKV), underscoring the urgent need for further research. This review explores the complex interplay between host immune responses and viral factors that lead from acute infection to chronic inflammation. Furthermore, it highlights key gaps in understanding viral persistence and immune evasion, and how to predict chronic diseases to improve therapeutic and preventive strategies against arthritogenic alphaviruses.

2025-12-31·Expert Review of Vaccines

Virus-like particles: a versatile and effective vaccine platform

Review

作者: Bachmann, Martin F. ; Lienert, Florian ; Schwarz, Tino F. ; van Damme, Pierre

INTRODUCTION:

Traditional live-attenuated or inactivated vaccines have limitations, including risks associated with uncontrolled replication, reduced immunogenicity, or production complexities. To address these issues, alternative platforms such as virus-like particles (VLPs) have been developed.

AREAS COVERED:

VLPs are self-assembling structures composed of viral proteins that mimic native viruses but are noninfectious. This review provides an overview of their structure, design and manufacture that make them an attractive platform for vaccine development. We then discuss the clinical development of some recently approved VLP vaccines and those widely used in immunization programs, summarizing the clinical trial data that underpins their efficacy and safety profiles. Additionally, we explore VLP vaccines in late-stage clinical development for respiratory syncytial virus and human metapneumovirus.

EXPERT OPINION:

VLPs are a versatile and promising platform for vaccine development. Their ability to mimic native viruses while eliminating the risks associated with live vaccines positions them as an attractive platform for vaccine design. Currently approved VLP vaccines demonstrate that they can provide effective protection against a wide range of diseases. Advances in VLP design and production are likely to lead to highly effective vaccines, significantly contributing to global immunization efforts.

2025-12-17·JOURNAL OF TRAVEL MEDICINE

Chikungunya vaccination for travellers: practical guidance for clinical decision-making

Review

作者: Staples, J Erin ; Chen, Lin H ; Schofield, Steven ; Shlim, David R ; Wilson, Mary E ; Hills, Susan L ; Barnett, Elizabeth D ; Christensen, Kristin J

Abstract:

Background:

Two vaccines have been licensed to prevent chikungunya, a live attenuated vaccine (IXCHIQ) manufactured by Valneva and a virus-like particle chikungunya vaccine (VIMKUNYA) manufactured by Bavarian Nordic. One or both vaccines are now available in many countries globally, including Brazil, Canada, United Kingdom, United States and some European countries and territories.

Key findings:

While the absence of a head-to-head study limits comparative inferences, the two vaccines have several different characteristics that should be considered when advising individual travellers. We outline key information on the vaccines including immunogenicity and safety data, recommendations for use in travellers and guidance for use in pregnancy and breastfeeding.

Conclusion:

Knowledge of the profiles and key features of the live attenuated and virus-like particle vaccines will enable healthcare providers to better advise travellers who are considering chikungunya vaccination.

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的新闻（医药）

2026-01-23

·GlobeNewswire-Health Care

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccinePotential to expand agreement to cover rest of Latin America COPENHAGEN, Denmark, January 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil. Eurofarma is also granted the right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America. The agreement is transfer price and royalty-based with no associated upfront or milestone payments. Eurofarma will be responsible for seeking and maintaining regulatory approval of the vaccine in exclusive territories, as well as sales and distribution costs. Bavarian Nordic will remain the manufacturer of the vaccine, which is made available to Eurofarma through a transfer price agreement. Pending discussions with the Brazilian Health Regulatory Agency, Anvisa, regulatory submission is expected to occur later in the first half of 2026, potentially supporting launch of the chikungunya vaccine in Brazil in the second half of 2027. “Following a successful launch of our chikungunya vaccine for travelers in the first Western markets in 2025, we are pleased to expand the commercial availability also for endemic populations through this first distribution agreement,” said Paul Chaplin, President & CEO of Bavarian Nordic. “Brazil remains severely impacted by chikungunya, representing half of all reported cases and related deaths worldwide. Together with Eurofarma, a local partner with strong regional presence, we continue our efforts to make a lasting impact on public health globally.” “Our partnership with Bavarian Nordic reinforces Eurofarma’s commitment to innovation and to expanding access to high‑quality healthcare. It builds on our strong capabilities to deliver high‑impact solutions for people in Brazil and across Latin America—so that everyone has the opportunity to live longer and better,” says João Siffert, Eurofarma’s Vice President of Innovation. While the agreement aims to significantly improve access to chikungunya vaccines in Brazil, it is not expected to have a material short- to medium-term financial impact on Bavarian Nordic. // About CHIKV VLPCHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. The vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 and the United Kingdom in May 2025 under the trade name VIMKUNYA®1. About chikungunyaChikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries2. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years3. In 2025, as of December, nearly 500,000 cases of chikungunya and over 200 associated deaths were reported worldwide4. More than half of the reported cases and associated deaths were reported from Brazil5. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile6. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. About EurofarmaFounded in 1972, Eurofarma covers key pharmaceutical segments and is the leader in medical prescriptions in Brazil. A Brazilian multinational company operating in 24 countries, with full coverage across Latin America and retail leadership in the region, the company also maintains operations in the United States and Africa, with more than 13,500 employees and 11 manufacturing facilities. In 2024, Eurofarma produced 600 million units. That same year, the company invested over USD 122 million in innovation projects and achieved net revenue exceeding USD 1.78 billion. For more information: www.eurofarma.com.br Contact investors:Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.comUS: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 1 Marketed as VIMKUNYA™ in the US. Marketed as VIMKUNYA® in EU and the United Kingdom. 2 World Health Organization (WHO). Chikungunya.https://www.who.int/news-room/fact-sheets/detail/chikungunya 3 European Centre for Disease Prevention and Control. Chikungunya virus disease. https://www.ecdc.europa.eu/en/chikungunya-virus-disease. 4 European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview. https://www.ecdc.europa.eu/en/chikungunya-monthly. 5 Pan American Health Organization (PAHO). Chikungunya: analysis by country. https://www.paho.org/en/arbo-portal/chikungunya-data-and-analysis/chikungunya-analysis-country 6 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

疫苗上市批准

2026-01-21

·医药经济报

FDA批准22款生物药折射的产业趋势与出海策略

全文3000字，快读如下： 2025年FDA共批准22款新生物药，本文从多个角度分析这些获批新药，如类别、给药方式、批准路径、热门领域等，并试图综合归纳出产业线索与创新药出海政策。在2025年度，美国食品药品监督管理局（FDA）经药品评价与研究中心（CDER）、生物制品评价与研究中心（CBER）共批准新生物药22款。整体结构呈现“三线并进”的鲜明特征：一端是以新冠与旅行医学为代表的疫苗产品回暖，另一端是以抗体药物与ADC为核心的肿瘤免疫持续加码，同时细胞与基因治疗在罕见病与高未满足需求领域继续扩容。若从机构口径看，CDER批准12款，CBER批准10款，显示出治疗性生物制品与预防性生物制品在同一年内同步放量的格局。多维概览获批新药在技术与类别构成上，抗体类产品仍是绝对主力，合计11款（2023年、2024年FDA批准抗体药数量分别为12、13款），其中既包括7款单抗，也包括1款双抗与2款ADC；值得注意的是，免疫检查点抑制剂还出现了与透明质酸酶复配以优化给药体验的组合制剂形态。细胞与基因治疗合计5款，覆盖自体细胞片、AAV基因替代、植入式封装细胞治疗装置等多条路径。疫苗方向则形成较为完整的谱系，包含1款mRNA疫苗、2款重组蛋白疫苗与1款结合疫苗，同时还有静脉用免疫球蛋白等传统生物制品在适应症与供给侧持续迭代。在疾病领域分布上，2025年新获批产品的ATC（解剖学治疗学及化学分类系统）一级分类以抗感染全身用药与抗肿瘤和免疫调节用药最为集中，分别对应6款与7款。与此同时，呼吸系统、感觉器官、皮肤、心血管、血液与造血系统等方向均有新产品进入，提示“高未满足需求的细分患者人群赛道”仍在持续贡献新增量。另有3款产品在ATC分配或归类上仍处于待定或尚未分配状态，这在一定程度上也反映出部分新机制与新形态产品在传统分类体系中的“先获批、后精细归类”的现实路径。在给药方式上，22款新生物药呈现出更鲜明的“门诊友好化”倾向。肌内注射产品达到5款，集中体现在疫苗与预防性产品；静脉输注仍占较大比例，共8款，主要分布在肿瘤、免疫与部分罕见病；皮下注射产品6款，成为推动患者可及性与依从性优化的重要形态；此外还出现局部贴敷的自体细胞片、鞘内单次基因治疗以及眼内植入胶囊式治疗装置等更具器械化与场景化特征的给药形态，使“生物药不止于分子本身，也在被给药系统重新定义”的产业趋势更为直观。加速与激励并用从监管工具与政策信号观察，2025年同样呈现出“加速与激励并用”的特征。全年共有4款采用加速批准路径，其中治疗性生物制品3款、疫苗1款，显示加速批准工具在年度内呈现出跨产品类型的应用特征。快速通道指定、突破性疗法指定与优先审评指定在当年亦较为活跃，分别达到6款、6款与7款产品。更值得产业关注的是“券机制”的再度显性化：1款产品触发热带病优先审评券，同时2款产品触发罕见儿科疾病优先审评券，其中还出现再生医学先进疗法指定与罕见儿科疾病优先审评券机制叠加的典型案例，使“以制度激励撬动高未满足需求领域创新”的政策导向更具可读性。热门领域核心看点在抗感染与疫苗方向，VIMKUNYA作为基孔肯雅热重组疫苗获批上市，兼具旅行医学与公共卫生应急的双重意义。其获批同时与热带病优先审评券机制形成联动，使疫苗产品在“疾病负担-政策工具-商业可持续”之间建立起更清晰的制度闭环。与之同日获批的PENMENVY作为五价脑膜炎球菌联合疫苗，将ACWY多糖结合疫苗与B组重组蛋白及外膜囊泡成分整合于同一产品体系，体现出疫苗平台向“更广覆盖、更少针次与更高依从性”演进的明确趋势。在新冠疫苗方面，MNEXSPIKE作为mRNA疫苗延续了平台路线的迭代节奏，强调在既有免疫基础之上进行适配性更新；Nuvaxovid作为重组蛋白疫苗则体现出“平台多样性”对供应韧性与不同人群接种偏好的现实价值。与治疗性生物制品相比，疫苗端更强调规模化制造、免疫学指标与公共卫生策略的协同，这也是其在年度结构中“数量不一定最多，但信号足够清晰”的原因所在。除疫苗外，Enflonsia作为用于RSV季节性预防的单抗产品，以肌内注射的方式将生物药进一步推向儿科与家庭场景，而QIVIGY等免疫球蛋白产品则继续支撑原发性体液免疫缺陷等领域的长期治疗与供给稳定。在肿瘤与免疫调节领域，2025年的核心看点仍然来自“抗体工程化与适应症选择的精细化”。Datroway作为TROP2靶向ADC，采用可切割连接子递送拓扑异构酶抑制剂载荷，反映出ADC在大适应症后线治疗市场中继续追求疗效增益与治疗窗优化的产业主线。与之对应，Emrelis作为c-Met靶向ADC在伴随诊断界定受益人群的前提下走加速批准路径，体现出FDA在ADC审评中对“人群富集策略”与“替代终点证据链”的持续重视。在T细胞衔接类药物方面，Lynozyfic作为BCMA×CD3双抗用于复发或难治多发性骨髓瘤，延续了血液瘤领域“高线数、强疗效信号、可管理安全性”的加速批准范式。此类产品通常在真实世界推广阶段面临给药管理、免疫相关不良反应与竞争产品快速迭代的多重挑战，但其对“肿瘤免疫进入更深疗程管理阶段”的标志意义依然明确。与此同时，Keytruda Qlex作为帕博利珠单抗与berahyaluronidase alfa的组合制剂，指向免疫检查点抑制剂从静脉输注向更便捷给药形态迁移的生命周期管理路径，其核心不在于改变分子机制，而在于通过给药体验与医疗资源占用的优化，巩固在高强度竞争环境中的综合优势。在免疫与罕见病领域，Voyxact作为靶向APRIL通路的IgA肾病治疗抗体走加速批准路径，体现出肾病慢病赛道在“蛋白尿改善—肾功能保护”证据链上的监管实践正在加速成熟。Imaavy作为FcRn通路抗体用于全身型重症肌无力，则反映出自身免疫疾病中“降低致病性IgG”这一路径的临床可复制性与商业可扩展性。 Andembry作为靶向凝血因子XIIa的遗传性血管性水肿预防单抗，则把接触系统上游机制带入成熟赛道竞争，显示出罕见病领域仍在用“更少给药、更稳控制与更强安全性叙事”争夺长期用药市场。在细胞与基因治疗板块，2025年的结构性信号尤为鲜明。Waskyra作为用于Wiskott-Aldrich综合征的基因治疗产品，不仅获得罕见儿科疾病优先审评券，还叠加再生医学先进疗法指定，构成当年最典型的“高未满足需求+制度工具叠加”的案例之一。ZEVASKYN作为用于隐性营养不良性大疱性表皮松解症的基因修饰自体表皮片/皮肤移植物（ex vivo 基因治疗属性的细胞/组织工程产品），以局部贴敷形式直接面向创面治疗场景，同时触发罕见儿科疾病优先审评券，显示出细胞与基因治疗正从“单纯分子创新”进一步走向“治疗系统创新”。在给药路径创新方面，ITVISMA将AAV9介导的基因替代疗法扩展为鞘内单次给药并拓展至更大年龄段人群，提示基因治疗的临床可达性正在通过给药通路与适用人群的拓展持续改善。与此同时，ENCELTO以眼内植入封装细胞治疗装置的方式实现持续给药，PAPZIMEOS则聚焦复发性呼吸道乳头状瘤病等专科罕见病，二者共同凸显出“器械化、场景化与专科化”将成为细胞与基因治疗下一阶段的重要产业语言。产业线索综合2025年FDA批准生物药的情况，可以归纳出三条较为清晰的产业线索。其一，孤儿药指定产品达到10款，罕见病及部分小患者群体适应症继续充当创新“密度最高”的试验场；其二，优先审评、突破性疗法、快速通道与加速批准在同一年内同时活跃，说明监管工具已被更系统地用于匹配不同证据链成熟度与不同未满足需求层级；其三，给药方式的多样化正在重塑竞争维度，皮下注射、植入装置、局部贴敷与鞘内通路等“治疗系统”要素，正与分子机制一起成为决定商业化效率与真实世界价值的关键变量。对于中国创新药产业而言，2025年的美国批准结构提示出更清晰的出海策略：在高未满足需求领域构建可审计证据链，在伴随诊断与人群富集上前置布局，并把给药体验与医疗资源占用的优化纳入产品定义，才能在下一轮全球竞争中获得更稳定的确定性。 [作者为泓惠医药科技（北京）有限责任公司首席科学家] 编辑：陈丽娜互校：陈淑文版式：陈丽娜审校：马飞阿斯利康“All in”中国CAR-T黄金靶点，科济药业、药明巨诺等同步发力真实世界证据或挂钩医保，8类药需重点关注省级挂网共识落地，比价小程序上线，2025药价治理十大工具全解析 www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

2026-01-20

·FiercePharma

Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation

Valneva's withdrawal of Ixchiq leaves Bavarian Nordic’s Vimkunya the only available chikungunya vaccine in the U.S. Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S.The French company announced the decision Monday, noting that the FDA has also opened an investigation into a newly reported serious adverse event.The FDA suspended Ixchiq’s approval in August after raising serious safety concerns related to the vaccine. At that time, the agency said it had received reports of one death from encephalitis “directly attributable” to the vaccine and more than 20 serious adverse events—hospitalizations and deaths—that were “consistent with chikungunya-like illness.”According to Valneva, the agency recently placed a clinical hold on Ixchiq’s development program to investigate a new case reported outside the U.S. The event involved a younger adult who received three vaccines together, including Ixchiq. Valneva described the case as “plausibly related to Ixchiq vaccination" but caveated that "causality has not been determined.”With an FDA accelerated approval in November 2023, Ixchiq became the world’s first shot for chikungunya. Its retreat leaves Bavarian Nordic’s Vimkunya the only available chikungunya vaccine in the U.S. To confirm Ixchiq’s efficacy and safety profile, Valneva has planned to start a post-marketing phase 4 program, including a randomized controlled efficacy and safety study for adults in endemic countries and an observational effectiveness study in Brazil. In its Jan. 19 release, the company said it “intends to move forward” with the post-marketing activities “subject to further discussions with relevant regulatory authorities.”With the withdrawal, it appears that Valneva does not wish to bring Ixchiq back to the U.S., even upon completing the post-marketing study.“This is a permanent decision,” a Valneva spokesperson told Fierce Pharma.“The withdrawal of our Ixchiq BLA in the U.S. does not have any impact on Valneva’s workforce,” the spokesperson added.As the vaccine was in its early launch phase and had been suspended since August, Valneva didn’t factor any U.S. Ixchiq sales into its projections for 2025 and beyond.Despite the safety issues and U.S. withdrawal, Valneva said it continues to engage with other health regulators in Europe, Canada, the U.K. and Brazil, where Ixchiq is licensed. While the vaccine’s various marketing authorizations target travelers, Valneva argues that “Ixchiq’s benefit-risk profile also remains favorable for people living in the endemic and outbreak settings.” RELATED Vaccine-focused Valneva consolidates R&D footprint by shuttering site, eliminating 30 rolesMeanwhile, Valneva investors’ focus remains on a potentially imminent phase 3 readout from VLA15, a Lyme disease vaccine partnered with Pfizer. There are about 476,000 annual cases of Lyme disease in the U.S. and 87 million people living in endemic regions in the country, with no vaccine currently available, according to Valneva.VLA15 uses a primary series of three doses, followed by a booster dose before the second tick season. That’s different from the two-plus-one regimens by LYMErix and ImuLyme, both of which were withdrawn from the market in the early 2000s amid poor market performance. VLA15’s efficacy will be evaluated after that second season in the phase 3 trial.

临床3期疫苗上市批准加速审批

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
基孔肯雅热	美国	Bavarian Nordic A/S	2025-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2025	临床2/3期	基孔肯雅热	3,141	CHIKV VLP vaccine	遞憲糧憲蓋淵膚夢醖鑰(構網鹽範廠襯醖範蓋製) = 繭夢築淵鹽築構鑰鏇構願蓋鬱繭選壓繭窪鑰選 (鑰齋衊淵鑰觸鑰獵壓夢 ) 更多	积极	2025-10-24
				Placebo	積艱網構壓餘醖窪糧醖(鹽繭簾窪繭觸築積鬱選) = 襯蓋齋鹹鏇範繭築獵鹹淵衊窪網蓋窪醖廠窪鹽 (鹹簾獵憲選餘鹹鹽糧選 )
NCT03992872 (Pubmed \| Lancet Microbe)	临床2期	甲病毒感染	60	Previous alphavirus vaccine recipients	積顧夢構鑰築鏇醖觸餘(網鹽醖遞鹽廠憲壓鬱範) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events 齋夢築夢遞簾壓夢窪築 (窪獵蓋蓋夢憲鹹壓繭鬱 )	积极	2025-04-01
				Alphavirus vaccine-naive controls
NCT05349617 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	鏇網膚顧範築鏇艱遞顧(鹹鹽襯糧蓋窪襯艱窪艱) = 糧願構憲壓範衊獵構鏇遞壓網襯衊襯網餘觸鬱 (醖醖選構襯顧窪餘鹽鏇, 582.3 ~ 892.7) 更多	积极	2025-02-14
				Placebo	鏇網膚顧範築鏇艱遞顧(鹹鹽襯糧蓋窪襯艱窪艱) = 鑰顧淵艱鹽遞觸鏇艱襯遞壓網襯衊襯網餘觸鬱 (醖醖選構襯顧窪餘鹽鏇, 6.5 ~ 10.0) 更多
NCT05072080 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	膚壓構膚蓋淵齋鹹廠齋(鹹願鬱積願製製淵製艱) = 遞觸夢積遞齋簾網鏇鑰鏇製觸窪構蓋壓製網憲 (築壓蓋顧艱選鏇鏇鏇壓, 1504.1 ~ 1695.6) 更多	积极	2025-02-14
				Placebo	膚壓構膚蓋淵齋鹹廠齋(鹹願鬱積願製製淵製艱) = 衊積顧遞鹹網願膚鏇網鏇製觸窪構蓋壓製網憲 (築壓蓋顧艱選鏇鏇鏇壓, 7.0 ~ 8.8) 更多
NCT05349617 (CTgov)	临床3期	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	築醖繭淵鹹醖製鏇顧憲 = 構鹹選廠顧簾壓鑰憲範蓋壓選艱鏇壓鏇襯夢積 (膚廠獵廠膚醖簾鏇繭範, 壓積選窪壓鹽衊醖憲醖 ~ 選網構鏇觸範獵醖鏇鏇) 更多	-	2024-12-13
				Placebo (Group 2 - Placebo)	築醖繭淵鹹醖製鏇顧憲 = 觸積鹹膚構顧築蓋範淵蓋壓選艱鏇壓鏇襯夢積 (膚廠獵廠膚醖簾鏇繭範, 選鹽憲簾齋餘構夢廠淵 ~ 選餘夢獵鑰齋衊夢壓鏇) 更多
NCT05072080 (CTgov)	临床3期	基孔肯雅热	3,258	CHIKV VLP/adjuvant (Group 1)	鏇觸鑰餘醖憲鏇齋窪餘 = 觸鏇鬱繭餘蓋構鹽繭襯選餘鹽簾蓋糧鏇廠構網 (餘簾鹽廠獵顧製夢願網, 淵鬱襯壓範積願積鬱鹹 ~ 醖艱壓鹽餘醖夢獵糧構) 更多	-	2024-08-30
				CHIKV VLP/adjuvant (Group 2)	鏇觸鑰餘醖憲鏇齋窪餘 = 糧鹽鹹觸鏇夢糧網膚鑰選餘鹽簾蓋糧鏇廠構網 (餘簾鹽廠獵顧製夢願網, 獵鹽顧鑰遞簾壓糧淵積 ~ 簾夢積鬱夢鹹壓膚衊範) 更多
NCT02562482 (phase 2, Pubmed \| Vaccine)	临床2期	基孔肯雅热 focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	餘鹽鬱鬱築鏇餘遞襯憲(餘醖夢範膚襯齋構製繭) = 簾醖獵網築窪範齋鏇遞襯衊鹽憲鏇範糧簾繭鹹 (艱糧顧鏇觸淵構繭艱壓 )	积极	2023-10-01
				CHIKV VLP vaccine seronegative recipients	餘鹽鬱鬱築鏇餘遞襯憲(餘醖夢範膚襯齋構製繭) = 繭鏇廠憲構顧網築餘餘襯衊鹽憲鏇範糧簾繭鹹 (艱糧顧鏇觸淵構繭艱壓 )
NCT05065983 (CHIKV VLP, CTgov)	临床2期	基孔肯雅热	25	CHIKV VLP, adjuvanted	鏇憲廠製襯壓築獵糧衊 = 構艱膚淵窪餘餘襯醖鬱蓋遞艱鹹窪夢鬱鏇鏇獵 (選襯鏇遞襯衊觸願窪艱, 築齋壓廠淵醖網鏇簾餘 ~ 鹽遞壓壓夢製憲積醖構) 更多	-	2023-02-28
NCT03992872 (WRAIR, Biospace) 人工标引	临床2期	甲病毒感染 \| 基孔肯雅热	60	PXVX 0317	範淵淵襯衊構壓糧觸顧(淵衊選選願構顧簾鏇糧) = The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. 鬱獵獵廠餘鏇窪鬱顧鑰 (夢餘餘艱糧鏇衊願遞構 )	积极	2022-11-01
NCT02562482 (Pubmed \| J Coll Physicians Surg Pak) 人工标引	临床2期	基孔肯雅热	400	PXVX-0317	觸鬱齋繭蓋夢網鹹鬱遞(膚鹹顧積遞鏇淵簾鹽構) = 壓鑰網願範觸獵觸廠餘憲鏇網獵網簾積觸築網 (夢夢艱窪窪鏇膚夢襯築 ) 更多	积极	2020-04-14
				Placebo	觸鬱齋繭蓋夢網鹹鬱遞(膚鹹顧積遞鏇淵簾鹽構) = 願構鏇夢範願壓積網淵憲鏇網獵網簾積觸築網 (夢夢艱窪窪鏇膚夢襯築 ) 更多